COMMUNIQUÉS West-GlobeNewswire

Teknova Launches Build-Tek™, a Proprietary AI Reagent Assistant That Allows Customers to Configure Complex Custom Product Requests in Minutes
05/08/2026
Therapeutic and diagnostic developers gain flexibility, speed, and scalability to advance custom formulations from preclinical research to manufacturing for clinical trials, with a reviewed quote returned in under three [...]
STERIS To Invest $600 Million to Build a Formulated Chemistries Manufacturing and Distribution Center of Excellence in North Carolina
05/08/2026
• This Formulated Chemistries Center of Excellence will support sterilization and disinfection for the global Healthcare and Pharmaceutical industries • This strategic manufacturing investment is the largest in STERIS’s [...]
IAOMT Supports HHS Directive to Phase Out Mercury Dental Fillings in Medicaid
05/08/2026
CHAMPIONS GATE, Fla., Aug. 05, 2026 (GLOBE NEWSWIRE) -- The International Academy of Oral Medicine and Toxicology (IAOMT) strongly endorses a historic directive from the U.S. Department of Health and Human Services (HHS [...]
BiomX Acquires 10% Stake in Motomea, Inventor of Advanced Electric Motor Technologies for Drone and Autonomous Systems
05/08/2026
Agreement includes an exclusive drone distribution license and an option to acquire a controlling interest in Motomea NETANYA, Israel, Aug. 05, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “ [...]
Adneuris Therapeutics Grants Exclusive License to Maruishi Pharmaceutical to Advance Cebranopadol in Japan and South Korea
05/08/2026
Agreement Grants Maruishi Rights for the Development and Commercialization of Cebranopadol for Pain in Japan and South Korea, Marking Adneuris' Second Ex-U.S. Licensing Transaction Under the Terms of the Agreement, [...]
Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026
05/08/2026
Company to host conference call to discuss financial results and provide a corporate update on August 12, 2026 at 4:30 p.m. ET SCOTTSDALE, Ariz., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey [...]
Intelligent Bio Solutions Completes Usability Study Supporting FDA 510(k) Submission
05/08/2026
Study confirms the system can be effectively administered by operators with no specialist background NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a [...]
Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program
05/08/2026
Purchasing $500,000 within First 30 days Since Program Commencement MELBOURNE, Australia, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical [...]
Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG
05/08/2026
Proteomedix Co-Founder and Proclarix® Co-Developer Returns to Company’s Board; Thomas Meier, PhD Re-Elected as Chairman at Annual General Meeting CINCINNATI, Ohio , Aug. 05, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. ( [...]
Vivos Therapeutics Announces Issuance of New US Patent Broadening Protection for Its Vivos CARE Oral Medical Device Technology
05/08/2026
Continuation Patent Secures Broader, Design Independent Claims, Building on the Company's 2024 Foundational Patent for Its Vibrational Oral Appliance Platform LITTLETON, Colo., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Vivos [...]
SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome
05/08/2026
TEL AVIV, Israel, Aug. 05, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company [...]
Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
05/08/2026
GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will [...]
Jupiter Neurosciences, Inc. Announces Reverse Stock Split
05/08/2026
Jupiter’s common stock is expected to begin trading on a post-split adjusted basis on August 7, 2026 JUPITER, FL, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company [...]
Nordic expands global team with new delivery capabilities to accelerate healthcare AI, analytics, managed services, and Epic support
05/08/2026
MADISON, Wis., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Nordic ® , a global healthcare IT consulting firm, announced the opening of a new delivery facility in Mexico as part of its continued global expansion. The new location [...]
Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
05/08/2026
ROCKVILLE, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company [...]
Lifeward Launches Pilot Program with Ottobock Care to Expand National Access to ReWalk® Personal Exoskeleton
05/08/2026
Ottobock Care , one of the leading mobility technology patient care organizations in the U.S. , bring s extensive clinical expertise and patient care infrastructure A dvances Lifeward’s strategy to broaden ReWalk access [...]
ImageneBio Reports Second Quarter 2026 Financial Results
05/08/2026
SAN DIEGO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) ("Imagene" or the "Company") today reported financial results for the quarter ended June 30, 2026, and provided a company update. Company [...]
UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights
05/08/2026
ZUSDURI ® generated $50.4 million in revenue in the second quarter of 2026, representing 73% quarter-over-quarter growth Once issued, new U.S. patent is expected to provide protection into July 2044 for ZUSDURI and UGN- [...]
Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis
05/08/2026
-- DMR-001 is a highly potent, long-acting antibody therapy targeting Type 1 and non-Type 1 mutant calreticulin (mutCALR), designed for convenient once-monthly subcutaneous dosing -- -- In preclinical studies, DMR-001 [...]

Pages